Liu, Dongyan
Hou, Xiaonan
Wu, Wangyu
Zanfagnin, Valentina
Li, Yunjian
Correia, Cristina
Zhao, Zhiyang
Zhao, Chenggang
Liu, Zhirong
Zhang, Tao
Fang, Zhiyou
Wang, Hongzhi
Xu, Chao http://orcid.org/0000-0003-0444-7080
Weroha, Saravut J.
Kaufmann, Scott H. http://orcid.org/0000-0002-4900-7145
Dai, Haiming http://orcid.org/0000-0002-0484-7407
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (P50 CA136393)
National Natural Science Foundation of China (21772201, 81572948)
Article History
Received: 30 November 2020
Revised: 8 April 2021
Accepted: 26 April 2021
First Online: 12 August 2021
Change Date: 26 October 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41419-021-04219-0
Competing interests
: The authors declare no competing interests.
: The animal studies of combination treatments were approved by the Ethics Committee of the Hefei Institutes of Physical Science, Chinese Academy of Sciences. For PDX experiments, all studies with human samples were approved by Mayo Clinic Institutional Review Board (IRB). All animal studies were carried out in accordance with the relevant guideline and regulations of the Mayo Clinic Institutional Animal Care and Use Committee. Written informed consent was obtained from all patients and documented in the electronic medical record. All tissues were coded with a patient heterotransplant (PH) number to protect patient identity in accordance with the Mayo Clinic IRB and Health Insurance Portability and Accountability Act regulations.